Literature DB >> 19718071

Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD.

A Pinomäki1, L Volin, L Joutsi-Korhonen, J O Virtanen, M Lemponen, T Ruutu, R Lassila.   

Abstract

The evolution of coagulation and fibrinolysis has not been thoroughly evaluated in allogeneic SCT. In this pilot study, we characterized the adaptive mechanisms of coagulation and fibrinolysis during allogeneic SCT and 3-month follow-up and studied possible associations with outcome, including acute GVHD. Thirty patients underwent SCT for a haematological malignancy after myeloablative conditioning. Nineteen patients received the transplant from an HLA-identical sibling and 11 from an unrelated donor. GVHD prophylaxis consisted of CYA and MTX, with methylprednisolone in sibling transplants. Serial coagulation and fibrinolytic activity markers were assessed, including prothrombin fragments 1+2 (F1+2), thrombin time, D-dimer, tissue-type plasminogen-activator (tPA) and plasminogen-activator inhibitor (PAI-1). Early during conditioning therapy, F1+2 and D-dimer increased threefold indicating thrombin generation and fibrin turnover. TPA activity peaked before engraftment, concurring with diminished PAI-1. At 10 days after transplantation shortened thrombin time (<15 s), F1+2 exceeding 0.7 nmol/L and PAI-1 3.0 IU/mL were associated with the development of GVHD. In conclusion, early maladaptation, that is, upregulated thrombin generation and inhibition of fibrinolysis, occurred in one-third of the SCT patients associating with the development of GVHD, a finding suggesting an interplay between coagulation and immunology during SCT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718071     DOI: 10.1038/bmt.2009.227

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking.

Authors:  A Sato; C Nishida; K Sato-Kusubata; M Ishihara; Y Tashiro; I Gritli; H Shimazu; S Munakata; H Yagita; K Okumura; Y Tsuda; Y Okada; A Tojo; H Nakauchi; S Takahashi; B Heissig; K Hattori
Journal:  Leukemia       Date:  2014-05-05       Impact factor: 11.528

2.  Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.

Authors:  Takashi Ishihara; Keiji Nogami; Tomoko Matsumoto; Akitaka Nomura; Yasufumi Takeshita; Satoshi Ochi; Midori Shima
Journal:  Int J Hematol       Date:  2017-03-16       Impact factor: 2.490

3.  Prophylaxis use of vitamin K1 improves coagulation function in hematopoietic stem cell transplantation patients: a retrospective cohort study.

Authors:  Yi Zhang; Xuan Lu; Liang V Tang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

4.  Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Authors:  Beata Przybyla; Anne Pinomäki; Jari Petäjä; Lotta Joutsi-Korhonen; Karin Strandberg; Andreas Hillarp; Ann-Kristin Öhlin; Tapani Ruutu; Liisa Volin; Riitta Lassila
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

Review 5.  Mini-review of kidney disease following hematopoietic stem cell transplant
.

Authors:  Ramy Sedhom; Daniel Sedhom; Edgar Jaimes
Journal:  Clin Nephrol       Date:  2018-06       Impact factor: 0.975

6.  Management of coagulation disorders in severe inflammation.

Authors:  Riitta Lassila; Robert Campbell
Journal:  Hemasphere       Date:  2019-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.